Abstract

Prostate cancer (PC) is one of the most common cancers affecting men. It may soon become the main cancer – caused mortality among men all over the world. The genetic basis of prostate cancer is very complex and its etiology is poorly understood. The genes associated with hereditary predisposition to prostate cancer remain largely unknown. Family history of PC, particularly at a young age, is a strong risk factor. Through linkage analysis, numerous prostate cancer susceptibility chromosomal loci have been identified, including: HPC1 (1q24-25), PCaP (1q42.2-43), HPCX (Xq27-28), CAPB (1p36), HPC2 (17p12), HPC20 (20q13). However, it turned out that any of these genes is not a high-risk prostate cancer susceptibility gene. According to literature data HPC is associated with genes involved in androgen metabolism, including androgen receptor gene – AR, SRD5A2 and CYP17, genes involved in the DNA damage repair, including BRCA1, BRCA2, NBS1 and MLH1 or some developmental genes as HOXB13. Identification of PC high predisposition susceptibility genes is very important, because the ascertainment of a higher risk of prostate cancer development in mutation carriers enable to develop and implement in clinical practice suitable prophylactic programs which could prevent the disease or detect it in an early stage. It seems that better knowledge of the molecular pathology of prostate cancer could make it easier to discover new drugs of chemopreventive and chemotherapeutic activity. There are many cellular pathways associated with PC cancerogenesis, which may become a potential goal for such drugs in the future.

References

• 1. Agalliu I., Kwon E.M., Zadory D., McIntosh L., Thompson J., StanfordJ.L., Ostrander E.A.: Germline mutations in the BRCA2 geneand susceptibility to hereditary prostate cancer. Clin. Cancer Res.,2007; 13: 839-843
  Google Scholar
• 2. Agalliu I., Leanza S.M., Smith L., Trent J.M., Carpten J.D., Bailey-WilsonJ.E., Burk R.D.: Contribution of HPC1 (RNASEL) and HPCX variantsto prostate cancer in a founder population. Prostate, 2010; 70: 1716-1727
  Google Scholar
• 3. Akbari M.R., Anderson L.N., Buchanan D.D., Clendenning M., JenkinsM.A., Win A.K., Hopper J.L., Giles G.G., Nam R., Narod S., GallingerS., Cleary S.P.: Germline HOXB13 p.Gly84Glu mutation and riskof colorectal cancer. Cancer Epidemiol., 2013; 37: 424-427
  Google Scholar
• 4. Alvarez-Cubero M.J., Saiz M., Martinez-Gonzalez L.J., Alvarez J.C.,Lorente J.A., Cozar J.M.: Genetic analysis of the principal genes relatedto prostate cancer: a review. Urol. Oncol., 2013; 31: 1419-1429
  Google Scholar
• 5. Badzioch M., Eeles R., Leblanc G., Foulkes W.D., Giles G., EdwardsS., Goldgar D., Hopper J.L., Bishop D.T., Møller P., Heimdal K., EastonD., Simard J.: Suggestive evidence for a site specific prostate cancergene on chromosome 1p36. J. Med. Genet., 2000; 37: 947-949
  Google Scholar
• 6. Barrow E., Hill J., Evans D.G.: Cancer risk in Lynch Syndrome.Fam. Cancer, 2013; 12: 229-240
  Google Scholar
• 7. Berry R., Schaid D.J., Smith J.R., French A.J., Schroeder J.J., McDonnellS.K., Peterson B.J., Wang Z.Y., Carpten J.D., Roberts S.G., TesterD.J., Blute M.L., Trent J.M., Thibodeau S.N.: Linkage analyses atthe chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36(CAPB) in families with hereditary prostate cancer. Am. J. Hum. Genet.,2000; 66: 539-546
  Google Scholar
• 8. Berry R., Schroeder J.J., French A.J., McDonnell S.K., PetersonB.J., Cunningham J.M., Thibodeau S.N., Schaid D.J.: Evidence for aprostate cancer-susceptibility locus on chromosome 20. Am. J. Hum.Genet., 2000; 67: 82-91
  Google Scholar
• 9. Berthon P., Valeri A., Cohen-Akenine A., Drelon E., Paiss T., WöhrG., Latil A., Millasseau P., Mellah I., Cohen N., Blanché H., Bellané–Chantelot C., Demenais F., Teillac P., Le Duc A. i wsp.: Predisposinggene for early onset prostate cancer localized on chromosome1q42.2-43. Am. J. Hum. Genet., 1998; 62: 1416-1424
  Google Scholar
• 10. Bisbal C., Silverman R.H.: Diverse functions of RNase L and implicationsin pathology. Biochimie, 2007; 89: 789-798
  Google Scholar
• 11. Bock C.H., Cunningham J.M., McDonnell S.K., Schaid D.J., PetersonB.J., Pavlic R.J., Schroeder J.J., Klein J., French A.J., Marks A.,Thibodeau S.N., Lange E.M., Cooney K.A.: Analysis of the prostatecancer-susceptibility locus HPC20 in 172 families affected by prostatecancer. Am. J. Hum. Genet., 2001; 68: 795-801
  Google Scholar
• 12. Breyer J.P., Avritt T.G., McReynolds K.M., Dupont W.D., SmithJ.R.: Confirmation of the HOXB13 G84E germline mutation in familialprostate cancer. Cancer Epidemiol. Biomarkers Prev., 2012;21: 1348-1353
  Google Scholar
• 13. Brookes C., Prosser D.O., Love J.M., Gardner R.J., Love D.R.: Diagnosticgenetics at a distance: von hippel-lindau disease and a novelmutation. Genet. Res. Int., 2013; 2013: 189196
  Google Scholar
• 14. Cancel-Tassin G., Latil A., Valéri A., Mangin P., Fournier G., BerthonP., Cussenot O.: PCAP is the major known prostate cancer predisposinglocus in families from south and west Europe. Eur. J. Hum.Genet., 2001; 9: 135-142
  Google Scholar
• 15. Cannon L.: Genetic epidemiology of prostate cancer in the UtahMormon genealogy. Cancer Survey, 1982; 1: 47-69
  Google Scholar
• 16. Carpten J., Nupponen N., Isaacs S., Sood R., Robbins C., Xu J.,Faruque M., Moses T., Ewing C., Gillanders E., Hu P., Bujnovszky P.,Makalowska I., Baffoe-Bonnie A., Faith D. i wsp.: Germline mutationsin the ribonuclease L gene in families showing linkage with HPC1.Nat. Genet., 2002; 30: 181-184
  Google Scholar
• 17. Carter B.S., Beaty T.H., Steinberg G.D., Childs B., Walsh P.C.: Mendelianinheritance of familial prostate cancer. Proc. Natl. Acad. Sci.USA, 1992; 89: 3367-3371
  Google Scholar
• 18. Carter B.S., Bova G.S., Beaty T.H., Steinberg G.D., Childs B., IsaacsW.B., Walsh P.C.: Hereditary prostate cancer: epidemiologic andclinical features. J. Urol., 1993; 150: 797-802
  Google Scholar
• 19. Cheung K.L., Khor T.O., Kong A.N.: Synergistic effect of combinationof phenethyl isothiocyanate and sulforaphane or curcuminand sulforaphane in the inhibition of inflammation. Pharm. Res.,2009; 26: 224-231
  Google Scholar
• 20. Colloca G., Venturino A.: The evolving role of familial historyfor prostate cancer. Acta Oncol., 2011; 50: 14-24
  Google Scholar
• 21. Crawford E.D.: Epidemiology of prostate cancer. Urology, 2003;62: 3-12
  Google Scholar
• 22. Crawford E.D.: Understanding the epidemiology, natural history,and key pathways involved in prostate cancer. Urology, 2009; 73: 4-10
  Google Scholar
• 23. Cybulski C.: Genetyka kliniczna raka prostaty. W: Genetyka klinicznanowotworów 2010. Red.: J. Lubiński. Print Group Sp. z.o.o.,Szczecin 2010, 177-189
  Google Scholar
• 24. Cybulski C., Górski B., Dębniak T., Gliniewicz B., MierzejewskiM., Masojć B., Jakubowska A., Matyjasik J., Złowocka E., Sikorski A.,Narod S.A., Lubiński J.: NBS1 is a prostate cancer susceptibility gene.Cancer Res., 2004; 64: 1215-1219
  Google Scholar
• 25. Cybulski C., Górski B., Gronwald J., Huzarski T., Byrski T., DębniakT., Jakubowska A., Wokołorczyk D., Gliniewicz B., Sikorski A.,Stawicka M., Godlewski D., Kwias Z., Antczak A., Krajka K. i wsp.:BRCA1 mutations and prostate cancer in Poland. Eur. J. Cancer Prev.,2008; 17: 62-66
  Google Scholar
• 26. Dadej R., Cieśliński P., Kwias Z.: Rak stercza. Współcz. Onkol.2002; 6: 108-116
  Google Scholar
• 27. Dandanell M., Friis-Hansen L., Sunde L., Nielsen F.C., HansenT.V.: Identification of 3 novel VHL germ-line mutations in DanishVHL patients. BMC Med. Genet., 2012; 13: 54-59
  Google Scholar
• 28. Datta M.W., Hernandez A.M., Schlicht M.J., Kahler A.J., DeGuemeA.M., Dhir R., Shah R.B., Farach-Carson C., Barrett A., Datta S.: Perlecan,a candidate gene for the CAPB locus, regulates prostate cancercell growth via the Sonic Hedgehog pathway. Mol. Cancer, 2006; 5: 9
  Google Scholar
• 29. Dean M., Lou H.: Genetics and genomics of prostate cancer. AsianJ. Androl., 2013; 15: 309-313
  Google Scholar
• 30. Di Masi A., Antoccia A.: NBS1 heterozygosity and cancer risk.Curr. Genomics, 2008; 9: 275-281
  Google Scholar
• 31. Dudkiewicz S.: Wprowadzenie do chorób stercza. W: Chorobystercza (gruczołu krokowego). Red.: S. Dudkiewicz. Poznań 2010,13-52
  Google Scholar
• 32. Edwards S.M., Evans D.G., Hope Q., Norman A.R., Barbachano Y.,Bullock S., Kote-Jarai Z., Meitz J., Falconer A., Osin P., Fisher C., GuyM., Jhavar S.G., Hall A.L., O’Brien L.T., et al.: Prostate cancer in BRCA2germline mutation carriers is associated with poorer prognosis. Br.J. Cancer, 2010; 103: 918-924
  Google Scholar
• 33. Edwards S.M., Kote-Jarai Z., Meitz J., Hamoudi R., Hope Q., OsinP., Jackson R., Southgate C., Singh R., Falconer A., Dearnaley D.P.,Ardern-Jones A., Murkin A., Dowe A., Kelly J. i wsp.: Two percent ofmen with early onset prostate cancer harbor germline mutationsin the BRCA2 gene. Am. J. Hum. Genet., 2003; 72: 1-12
  Google Scholar
• 34. Fachal L., Gómez-Caamaño A., Celeiro-Muñoz C., Peleteiro P.,Blanco A., Carballo A., Forteza J., Carracedo A., Vega A.: BRCA1 mutationsdo not increase prostate cancer risk: results from a meta–analysis including new data. Prostate, 2011; 71: 1768-1779
  Google Scholar
• 35. Filus A., Mędraś M., Kuliczkowska-Płaksej J., Trzmiel-Bira A.,Łaczmański Ł., Jędrzejuk D.: Występowanie polimorfizmu sekwencjitrójnukleotydowej CAG genu receptora androgenowego w populacjiwielkomiejskiej polskich mężczyzn. Endokrynol. Pol., 2009; 60: 263-270
  Google Scholar
• 36. Fredriksson H., Ikonen T., Autio V., Matikainen M.P., Helin H.J.,Tammela T.L., Koivisto P.A., Schleutker J.: Identification of germlineMLH1 alterations in familial prostate cancer. Eur. J. Cancer, 2006;42: 2802-2806
  Google Scholar
• 37. Futaki M., Liu J.M.: Chromosomal breakage syndromes and theBRCA1 genome surveillance complex. Trends Mol. Med., 2001; 7:560-565
  Google Scholar
• 38. Gallagher D.J., Gaudet M.M., Pal P., Kirchhoff T., Balistreri L.,Vora K., Bhatia J., Stadler Z., Fine S.W., Reuter V., Zelefsky M., MorrisM.J., Scher H.I., Klein R.J., Norton L. i wsp.: Germline BRCA mutationsdenote a clinicopathologic subset of prostate cancer. Clin. CancerRes., 2010; 16: 2115-2121
  Google Scholar
• 39. Goode E.L., Stanford J.L., Chakrabarti L., Gibbs M., Kolb S., McIndoeR.A., Buckley V.A., Schuster E.F., Neal C.L., Miller E.L., BrandzelS., Hood L., Ostrander E.A., Jarvik G.P.: Linkage analysis of 150 high–risk prostate cancer families at 1q24-25. Genet. Epidemiol., 2000;18: 251-275
  Google Scholar
• 40. Goode E.L., Stanford J.L., Peters M.A., Janer M., Gibbs M., Kolb S.,Badzioch M.D., Hood L., Ostrander E.A., Jarvik G.P.: Clinical characteristicsof prostate cancer in an analysis of linkage to four putativesusceptibility loci. Clin. Cancer Res., 2001; 7: 2739-2749
  Google Scholar
• 41. Grönberg H., Isaacs S.D., Smith J.R., Carpten J.D., Bova G.S., FreijeD., Xu J., Meyers D.A., Collins F.S., Trent J.M., Walsh P.C., Isaacs W.B.:Characteristics of prostate cancer in families potentially linked to thehereditary prostate cancer 1 (HPC1) locus. JAMA, 1997; 278: 1251-1255
  Google Scholar
• 42. Gsur A., Bernhofer G., Hinteregger S., Haidinger G., Schatzl G.,Madersbacher S., Marberger M., Vutuc C., Micksche M.: A polymorphismin the CYP17 gene is associated with prostate cancer risk. Int.J. Cancer, 2000; 87: 434-437
  Google Scholar
• 43. Hartwig M., Janiszewska H., Bąk A., Pilarska M., Heise M., Junkiert-CzarneckaA., Laskowski R., Haus O.: Prevalence of the BRCA1c.68_69delAG (BIC: 185delAG) mutation in women with breast cancerfrom north-central Poland and a review of the literature on otherregions of the country. Współcz. Onkol., 2013; 17: 34-37
  Google Scholar
• 44. Hebbring S.J., Fredriksson H., White K.A., Maier C., Ewing C.,McDonnell S.K., Jacobsen S.J., Cerhan J., Schaid D.J., Ikonen T., AutioV., Tammela T.L., Herkommer K., Paiss T., Vogel W. i wsp.: Role of theNijmegen breakage syndrome 1 gene in familial and sporadic prostatecancer. Cancer Epidemiol. Biomarkers Prev., 2006; 15: 935-938
  Google Scholar
• 45. Hickson I.D.: RecQ helicases: caretakers of the genome. Nat. Rev.Cancer, 2003; 3: 169-178
  Google Scholar
• 46. Hsing A.W., Chokkalingam A.P.: Prostate cancer epidemiology.Front. Biosci., 2006; 11: 1388-1413
  Google Scholar
• 47. Hu S.Y., Liu T., Liu Z.Z., Ledet E., Velasco-Gonzalez C., MandalD.M., Koochekpour S.: Identification of a novel germline missensemutation of the androgen receptor in African American men withfamilial prostate cancer. Asian J. Androl., 2010; 12: 336-343
  Google Scholar
• 48. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D.: Globalcancer statistics. CA Cancer J. Clin., 2011; 61: 69-90
  Google Scholar
• 49. Kirsh V.A., Peters U., Mayne S.T., Subar A.F., Chatterjee N., JohnsonC.C., Hayes R.B.: Prostate, Lung, Colorectal and Ovarian CancerScreening Trial: Prospective study of fruit and vegetable intake andrisk of prostate cancer. J. Natl. Cancer Inst., 2007; 99: 1200-1209
  Google Scholar
• 50. Klusek J., Głuszek S., Klusek J.: Wybrane mutacje związane zdużym ryzykiem wystąpienia nowotworów jelita grubego. Przegl.Gastroenterol., 2012; 7: 1-6
  Google Scholar
• 51. Kluźniak W., Wokołorczyk D., Kashyap A., Jakubowska A., GronwaldJ., Huzarski T., Byrski T., Dębniak T., Gołąb A., Gliniewicz B., SikorskiA., Świtała J., Borkowski T., Borkowski A., Antczak A. i wsp.:The G84E mutation in the HOXB13 gene is associated with an increasedrisk of prostate cancer in Poland. Prostate, 2013; 73: 542-548
  Google Scholar
• 52. Kładny J., Kurzawski G., Suchy J., Lubiński J.: Zespół Lyncha(HNPCC). W: Genetyka kliniczna nowotworów 2010. Red.: J. Lubiński.Print Group Sp. z.o.o., Szczecin 2010, 85-96
  Google Scholar
• 53. Kral M., Rosińska V., Student V., Grepl M., Hrabec M., Bouchal J.:Genetic determinants of prostate cancer: a review. Biomed. Pap. Med.Fac. Univ. Palacky Olomouc. Czech Repub., 2011; 155: 3-9
  Google Scholar
• 54. Kurahashi N., Inoue M., Iwasaki M., Sasazuki S., Tsugane A.S.;Japan Public Health Center-Based Prospective Study Group: Dairyproduct, saturated fatty acid, and calcium intake and prostate cancerin a prospective cohort of Japanese men. Cancer Epidemiol. BiomarkersPrev., 2008; 17: 930-937
  Google Scholar
• 55. Leitzmann M.F., Rohrmann S.: Risk factors for the onset of prostaticcancer: age, location, and behavioral correlates. Clin. Epidemiol.,2012; 4: 1-11
  Google Scholar
• 56. Leongamornlert D., Mahmud N., Tymrakiewicz M., Saunders E.,Dadaev T., Castro E., Goh C., Govindasami K., Guy M., O’Brien L., SawyerE., Hall A., Wilkinson R., Easton D., The UKGPCS Collaborators,et al.: Germline BRCA1 mutations increase prostate cancer risk. Br.J. Cancer, 2012; 106: 1697-1701
  Google Scholar
• 57. Li D., Kumaraswamy E., Harlan-Williams L.M., Jensen R.A.: Therole of BRCA1 and BRCA2 in prostate cancer. Front. Biosci., 2013;18: 1445-1459
  Google Scholar
• 58. Li X., Huang Y., Fu X., Chen C., Zhang D., Yan L., Xie Y., Mao Y.,Li Y.: Meta-analysis of three polymorphisms in the steroid-5-alpha–reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostatecancer. Mutagenesis, 2011; 26: 371-383
  Google Scholar
• 59. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J.,Koskenvuo M., Pukkala E., Skytthe A., Hemminki K.: Environmentaland heritable factors in the causation of cancer – analyses ofcohorts of twins from Sweden, Denmark, and Finland. N. Engl. J.Med., 2000; 343: 78-85
  Google Scholar
• 60. Licznerska B., Bear-Dubowska W.: Intrakrynologia estrogenówa terapia i chemioprewencja w nowotworach piersi. Postępy Hig.Med. Dośw., 2010; 64: 220-230
  Google Scholar
• 61. Loukola A., Chadha M., Penn S.G., Rank D., Conti D.V., ThompsonD., Cicek M., Love B., Bivolarevic V., Yang Q., Jiang Y., Hanzel D.K.,Dains K., Paris P.L., Casey G. i wsp.: Comprehensive evaluation of theassociation between prostate cancer and genotypes/haplotypes inCYP17A1, CYP3A4 and SRD5A2. Eur. J. Hum. Genet., 2004; 12: 321-332
  Google Scholar
• 62. Machoy P., Lubiński J.: Dziedziczny rak prostaty. Urol. Pol., 2002;55: 41-43
  Google Scholar
• 63. Makridakis N.M., Ross R.K., Pike M.C., Crocitto L.E., Kolonel L.N.,Pearce C.L., Henderson B.E., Reichardt J.K.: Association of mis-sensesubstitution in SRD5A2 gene with prostate cancer in African-Americanand Hispanic men in Los Angeles, USA. Lancet, 1999; 354: 975-978
  Google Scholar
• 64. Martin N.E., Mucci L.A., Loda M., DePinho R.A.: Prognostic determinantsin prostate cancer. Cancer J., 2011; 17: 429-437
  Google Scholar
• 65. Matuszewska K., Matuszewski M., Jassem J.: Rola badań przesiewowychw raku gruczołu krokowego. Współcz. Onkol., 2003; 7:160-165
  Google Scholar
• 66. Matych M.: Znaczenie hormonów steroidowych w etiopatogenezieraka gruczołu krokowego. Urol. Pol., 2006; 59: 83-86
  Google Scholar
• 67. Medeiros R., Morais A., Vasconcelos A., Costa S., Pinto D., OliveiraJ., Lopes C.: The role of vitamin D receptor gene polymorphisms inthe susceptibility to prostate cancer of a southern European population.J. Hum. Genet., 2002; 47: 413-418
  Google Scholar
• 68. Mehta M., Sethi S., Pushker N., Kashyap S., Sen S., Bajaj M.S.,Ghose S.: Retinoblastoma. Singapore Med. J., 2012; 53: 128-135
  Google Scholar
• 69. Meyer M.S., Penney K.L., Stark J.R., Schumacher F.R., Sesso H.D.,Loda M., Fiorentino M., Finn S., Flavin R.J., Kurth T., Price A.L., GiovannucciE.L., Fall K., Stampfer M.J., Ma J. i wsp.: Genetic variationin RNASEL associated with prostate cancer risk and progression.Carcinogenesis, 2010; 31: 1597-1603
  Google Scholar
• 70. Miller E.A., Stanford J.L., Hsu L., Noonan E., Ostrander E.A.: Polymorphicrepeats in the androgen receptor gene in high-risk sibships.Prostate, 2001; 48: 200-205
  Google Scholar
• 71. Mononen N., Ikonen T., Syrjäkoski K., Matikainen M., SchleutkerJ., Tammela T.L., Koivisto P.A., Kallioniemi O.P.: A missense substitutionA49T in the steroid 5-alpha-reductase gene (SRD5A2) isnot associated with prostate cancer in Finland. Br. J. Cancer, 2001;84: 1344-1347
  Google Scholar
• 72. Montgomery J.S., Price D.K., Figg W.D.: The androgen receptorgene and its influence on the development and progression of prostatecancer. J. Pathol., 2001; 195: 138-146
  Google Scholar
• 73. Moran A., O’Hara C., Khan S., Shack L., Woodward E., MaherE.R., Lalloo F., Evans D.G.: Risk of cancer other than breast or ovarianin individuals with BRCA1 and BRCA2 mutations. Fam. Cancer,2012; 11: 235-242
  Google Scholar
• 74. Mould R.F.: Prostate cancer incidence review with emphasis onpublications from the American Cancer Society & the InternationalAgency for Research on Cancer. Nowotwory J. Oncol., 2002; 52: 11-15
  Google Scholar
• 75. Nacusi L.P., Tindall D.J.: Targeting 5α-reductase for prostatecancer prevention and treatment. Nat. Rev. Urol., 2011; 8: 378-384
  Google Scholar
• 76. Ostrander E.A., Stanford J.L.: Genetics of prostate cancer: toomany loci, too few genes. Am. J. Hum. Genet., 2000; 67: 1367-1375
  Google Scholar
• 77. Parkin D.M., Bray F., Ferlay J., Pisani P.: Global cancer statistics, 2002 CA Cancer J. Clin., 2005; 55: 74-108
  Google Scholar
• 78. Peters M.A., Jarvik G.P., Janer M., Chakrabarti L., Kolb S., GoodeE.L., Gibbs M., DuBois C.C., Schuster E.F., Hood L., Ostrander E.A.,Stanford J.L.: Genetic linkage analysis of prostate cancer familiesto Xq27-28. Hum. Hered., 2001; 51: 107-113
  Google Scholar
• 79. Powell I.J., Meyskens F.L. Jr.: African American men and hereditary/familialprostate cancer: Intermediate-risk populations forchemoprevention trials. Urology, 2001; 57: 178-181
  Google Scholar
• 80. Qin L.Q., Xu J.Y., Wang P.Y., Tong J., Hoshi K.: Milk consumptionis a risk factor for prostate cancer in Western countries: evidencefrom cohort studies. Asia Pac. J. Clin. Nutr., 2007; 16: 467-476
  Google Scholar
• 81. Rebbeck T.R., Walker A.H., Zeigler-Johnson C., Weisburg S., MartinA.M., Nathanson K.L., Wein A.J., Malkowicz S.B.: Association ofHPC2/ELAC2 genotypes and prostate cancer. Am. J. Hum. Genet.,2000; 67: 1014-1019
  Google Scholar
• 82. Rodríguez-González G., Cabrera S., Ramírez-Moreno R., BilbaoC., Díaz-Chico J.C., Serra L., Chesa N., Cabrera J.J., Díaz-Chico B.N.:Short alleles of both GGN and CAG repeats at the exon-1 of the androgenreceptor gene are associated to increased PSA staining and ahigher Gleason score in human prostatic cancer. J. Steroid Biochem.Mol. Biol., 2009; 113: 85-91
  Google Scholar
• 83. Rökman A., Ikonen T., Mononen N., Autio V., Matikainen M.P.,Koivisto P.A., Tammela T.L., Kallioniemi O.P., Schleutker J.: ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. CancerRes., 2001; 61: 6038-6041
  Google Scholar
• 84. Rökman A., Ikonen T., Seppälä E.H., Nupponen N., Autio V., MononenN., Bailey-Wilson J., Trent J., Carpten J., Matikainen M.P.,Koivisto P.A., Tammela T.L., Kallioniemi O.P., Schleutker J.: Germlinealterations of the RNASEL gene, a candidate HPC1 gene at 1q25,in patients and families with prostate cancer. Am. J. Hum. Genet.,2002; 70: 1299-1304
  Google Scholar
• 85. Romanowicz H., Smolarz B., Fiks T., Kulig A., Połać I., SobczukA., Pertyński T.: Znaczenie mechanizmu naprawy DNA błędnie sparowanychzasad azotowych (MMR) w raku piersi. Przegl. Menopauz.,2010; 2: 95-100
  Google Scholar
• 86. Schaid D.J., McDonnell S.K., Blute M.L., Thibodeau S.N.: Evidencefor autosomal dominant inheritance of prostate cancer. Am. J. Hum.Genet., 1998; 62: 1425-1438
  Google Scholar
• 87. Siegel R., Ma J., Zou Z., Jemal A.: Cancer statistics, 2014. CA CancerJ. Clin., 2014; 64: 9-29
  Google Scholar
• 88. Simard J., Dumont M., Soucy P., Labrie F.: Perspective: prostatecancer susceptibility genes. Endocrinology, 2002; 143: 2029-2040
  Google Scholar
• 89. Skałba P., Dąbkowska-Huć A., Bednarska-Czerwińska A.: Receptorandrogenowy. Gin. Prakt., 2003; 11: 12-18
  Google Scholar
• 90. Smart R.: PSA testing and DRE, TRUS scanning with sector biopsy,improved histology, curative treatments, and active surveillancefor prostate cancer: a success story for men’s health. N Z Med. J.,2008; 121: 57-68
  Google Scholar
• 91. Smith J.R, Freije D., Carpten J.D., Grönberg H., Xu J., Isaacs S.D.,Brownstein M.J., Bova G.S., Guo H., Bujnovszky P., Nusskern D.R.,Damber J.E., Bergh A., Emanuelsson M., Kallioniemi O.P. i wsp.: Majorsusceptibility locus for prostate cancer on chromosome 1 suggestedby a genome wide search. Science, 1996; 274: 1371-1374
  Google Scholar
• 92. Soggia P., Madonia M., Corbu C.: Current role of prostatic transrectalultrasound in the diagnosis of CaP. Urologia, 2012; 79: 130-134
  Google Scholar
• 93. Sorrell A.D., Espenschied C.R., Culver J.O., Weitzel J.N.: Tumorprotein p53 (TP53) testing and Li-Fraumeni syndrome: current statusof clinical applications and future directions. Mol. Diagn. Ther.,2013; 17: 31-47
  Google Scholar
• 94. Stasiewicz D., Starosławska E., Brzozowska A., Mocarska A., ŁosickiM., Szumiło J., Burdan F.: Epidemiology and risk factors of theprostate cancer. Pol. Merkur. Lekarski, 2012; 33: 163-167
  Google Scholar
• 95. Steinberg G.D., Carter B.S., Beaty T.H., Childs B., Walsh P.C.: Familyhistory and the risk of prostate cancer. Prostate, 1990; 17: 337-347
  Google Scholar
• 96. Stott-Miller M., Karyadi D.M., Smith T., Kwon E.M., Kolb S., StanfordJ.L., Ostrander E.A.: HOXB13 mutations in a population-based,case-control study of prostate cancer. Prostate, 2013; 73: 634-641
  Google Scholar
• 97. Taioli E., Sears V., Watson A., Flores-Obando R.E., JacksonM.D., Ukoli F.A., de Syllos Cólus I.M., Fernandez P., McFarlane–Anderson N., Ostrander E.A., Rodrigues I.S., Stanford J.L., TaylorJ.A., Tulloch-Reid M., Ragin C.C.: Polymorphisms in CYP17 andCYP3A4 and prostate cancer in men of African descent. Prostate,2013; 73: 668-676
  Google Scholar
• 98. Tavtigian S.V., Simard J., Teng D.H., Abtin V., Baumgard M., BeckA., Camp N.J., Carillo A.R., Chen Y., Dayananth P., Desrochers M.,Dumont M., Farnham J.M., Frank D., Frye C. i wsp.: A candidate prostatecancer susceptibility gene at chromosome 17p. Nat. Genet.,2001; 27: 172-180
  Google Scholar
• 99. Terlikiewicz J., Makarewicz R., Lebioda A., Wronczewska A., KabacińskaR., Zuchora A.: Ocena objętości gruczołu krokowego przyużyciu TRUS i NMR u chorych na raka stercza. Współcz. Onkol.,2006; 10: 459-463
  Google Scholar
• 100. Tomczyk J., Olejnik A.: Sulforafan – potencjalny czynnik w prewencjii terapii chorób nowotworowych. Postępy Hig. Med. Dośw.,2010; 64: 590-603
  Google Scholar
• 101. Wang L., McDonnell S.K., Elkins D.A., Slager S.L., ChristensenE., Marks A.F., Cunningham J.M., Peterson B.J., Jacobsen S.J., CerhanJ.R., Blute M.L., Schaid D.J., Thibodeau S.N.: Role of HPC2/ELAC2 inhereditary prostate cancer. Cancer Res., 2001; 61: 6494-6499
  Google Scholar
• 102. Weissman S.M., Weiss S.M., Newlin A.C.: Genetic testing bycancer site: ovary. Cancer J., 2012; 18: 320-327
  Google Scholar
• 103. Wojciechowska U., Didkowska J., Zatoński W.: Zachorowania nanowotwory złośliwe – tabele i rysunki. W: Nowotwory złośliwe w Polscew 2006 roku. Red.: W. Zatoński. WEDA s.c., Warszawa 2010, 49-86
  Google Scholar
• 104. Woolf C.M.: An investigation of familial aspects of carcinomaof the prostate. Cancer, 1960; 13: 739-744
  Google Scholar
• 105. Xu B., Tong N., Li J.M., Zhang Z.D., Wu H.F.: ELAC2 polymorphismsand prostate cancer risk: a meta-analysis based on 18 case–control studies. Prostate Cancer Prostatic Dis., 2010; 13: 270-277
  Google Scholar
• 106. Xu J. and the International Consortium for Prostate Cancer Genetics:Combined analysis of hereditary prostate cancer linkage to1q24-25: results from 772 hereditary prostate cancer families fromthe International Consortium for Prostate Cancer Genetics. Am. J.Hum. Genet., 2000; 66: 945-957
  Google Scholar
• 107. Xu J., Meyers D., Freije D., Isaacs S., Wiley K., Nusskern D.,Ewing C., Wilkens E., Bujnovszky P., Bova G.S., Walsh P., Isaacs W.,Schleutker J., Matikainen M., Tammela T. i wsp.: Evidence for a prostatecancer susceptibility locus on the X chromosome. Nat. Genet.,1998; 20: 175-179
  Google Scholar
• 108. Yeh C.C., Lee C., Dahiya R.: DNA mismatch repair enzyme activityand gene expression in prostate cancer. Biochem. Biophys. Res.Commun., 2001; 285: 409-413
  Google Scholar

Full text